MMP10 is highly expressed in an osteosarcoma stem cell model and predicts poor prognosis.

Quantitative immunoassays of matrix Metalloproteinase-9 in tears using a contact Lens.

1,10-Phenanthroline enhances dentin bond durability via dual-site binding to collagen and matrix Metalloproteinase-8.

Ednrb-driven ET-1/RXFP1 underlies TXA-induced exacerbation of acute cartilage injury-related PTOA.

α7nAChR inhibits pyroptosis of rheumatoid arthritis synovial fibroblasts via the NLRP3/GSDMD pathway.

Senescent cancer-associated fibroblasts in cancer progression: From formation to therapeutic opportunities.

Combined treatment with tPA and Chinese herbal medicine for ischemic stroke: is it valuable?

Skin aging is characterized by a progressive decline in regenerative capacity, primarily driven by fibroblast senescence, oxidative stress, chronic inflammation, and the degradation of type I/III collagen, culminating in an extracellular matrix (ECM) imbalance. Current injectable fillers-such as hyaluronic acid, collagen, and PLLA-provide temporary structural support but fail to address the underlying cellular senescence or restore ECM homeostasis, highlighting the need for regenerative biomaterials. Silk fibroin (SF), a natural protein, self-assembles into a β-sheet-rich scaffold that structurally supports fibroblasts in depositing collagen and elastin, thereby improving the skin's ECM, accelerating wound healing, and promoting tissue regeneration. However, its role in modulating fibroblast senescence and ECM remodeling remains unclear. This study demonstrates that SF provides a suitable microenvironment for the adhesion and proliferation of fibroblasts, reducing the accumulation of SASP factors and facilitating the transition of fibroblasts from a senescent to a functional state. Furthermore, SF improves the skin microenvironment by reducing reactive oxygen species (ROS) and matrix metalloproteinase (MMP) expression through modulation of the ROS-MAPK-AP-1-MMP signal pathway, thereby delaying collagen degradation in aged skin. These findings reveal that SF uniquely rejuvenates fibroblasts and restores ECM homeostasis through a non-inflammatory mechanism, distinguishing it from conventional fillers that rely on inflammatory pathways for collagen induction. This work establishes SF as a next-generation injectable biomaterial with dual targeting of cellular senescence and ECM imbalance, offering a transformative strategy for regenerative dermatology and personalized anti-aging approaches.

ECM-responsive nanomedicine to enhance immunotherapy in pancreatic cancer.

Antimicrobial resistance poses a serious threat to global food safety and poultry production, prompting the need for effective alternatives to conventional antibiotics in food-producing animals. In this study, a recombinant food-grade strain, L. lactis NZ-BB, was engineered to express a fusion antimicrobial peptide (BMAP18-BSN37), and evaluated its probiotic characteristics and antimicrobial efficacy against Salmonella, a major foodborne pathogen in chicken. The recombinant plasmid pUBB was successfully constructed and introduced into L. lactis NZ9000, with optimal peptide expression achieved following Nisin induction (20 ng/mL, 6 h). NZ-BB demonstrated stable plasmid maintenance, high expression levels, and no detectable metabolic burden. In vivo trials using BALB/c murine and 817 strain avian models showed that NZ-BB enhanced body weight gain, supported immune organ development, and improved intestinal barrier integrity through upregulation of tight junction proteins (occludin, claudin-1, ZO-1) and anti-inflammatory cytokines (TGF-β, IL-4), while reducing pro-inflammatory markers (IL-1β, TNF-α, IL-17a). Importantly, oral administration of NZ-BB significantly reduced intestinal and systemic Salmonella burdens, mitigated tissue damage, and restored immune balance in both mice and chicks. Furthermore, NZ-BB regulated the expression of innate immune receptors (e.g., NLRC3) and matrix metalloproteinases (e.g., MMP-1), highlighting its immunomodulatory potential. These results underscore the dual probiotic and antimicrobial functionality of NZ-BB and support its potential use as a food-safe microbial agent to improve animal health and reduce the risk of Salmonella contamination in the food chain.

Engineered bacterial outer membrane vesicles enhanced tumor immunotherapy through remodeling tumor stroma and targeted delivery of CD73 siRNA.

Investigating the therapeutic potential of nasal administration of mitochondria on blood-brain barrier integrity and vasogenic brain Edema in a rat ischemic stroke model.

Pyrroloquinoline quinone alleviates age-related osteoarthritis via nuclear factor erythroid 2-related factor 2-mediated stress response and insulin-like growth factor 1 receptor upregulation.

Ethnopharmacological evaluation of Vitellaria paradoxa triterpenes for wound healing: In vivo evidence of lupeol and α/β-amyrin in promoting dermal regeneration.

Core regulatory mechanisms of macrophage dynamic polarization and multicellular interaction networks in driving venous thromboembolism.

Hypoxia-responsive self-assembled nanoparticles for reprogramming tumor-associated macrophages into an anti-tumor M1 phenotype in breast cancer.

Inhibitory effect of Anwulignan on the IL-36R/TLR9 signaling pathway: potential therapeutic role in hepatic fibrosis.

To investigate the safety, tolerability, pharmacokinetic profile, and efficacy of SJP-0132 in participants with dry eye disease (DED). Phase 1/2, randomized, double-masked, single-center, placebo-controlled single and multiple ascending dose study. Generally healthy adults aged ≥18 years with a patient-reported history of DED for ≥6 months, eye dryness visual analog scale (VAS: 0-100) ≥40 mm, 5-item dry eye questionnaire (DEQ-5) ≥6, and central corneal fluorescein staining (CFS) of 2 to 4 (Baylor scale: 0-5 for each of five zones). This study consisted of Part A and Part B, containing four single- and two multiple-ascending dose cohorts, respectively. Following a 14-day placebo run-in, participants were randomized 1:3 to receive a single dose of placebo or SJP-0132 in each cohort in Part A. In Part B, participants were randomized 1:2 to receive placebo or SJP-0132 four times daily for 4 weeks in each cohort. The primary outcomes were the number and severity of adverse events, plasma concentration, and mean change from baseline in eye dryness VAS at 4 hours on Day 29 and in CFS score at the central zone on Day 29. Secondary end points included total CFS of all 5 zones, conjunctival staining, tear film break-up time, additional dry eye symptom VAS, DEQ-5, and tear matrix metalloproteinase-9. Twenty-nine and 60 participants were randomized to Part A and B, respectively. Two of 21 and 6 of 40 participants who received SJP-0132 in each part reported at least one treatment-emergent adverse event (TEAE), compared with 0 of 8 and 7 of 20 for placebo. All TEAEs were mild. Plasma concentrations increased dose dependently. Eye dryness VAS decreased as early as 30 minutes after the first dose in the 0.1% and 0.3% groups in Part A and in the 0.3% group in Part B. The decrease persisted throughout the treatment period, although it was not statistically significant versus placebo. CFS scores decreased throughout the treatment period with a dose dependence similar to VAS. SJP-0132 was safe and well tolerated, plasma concentrations increased dose dependently, and efficacy data indicated that it improved both signs and symptoms of DED with a rapid onset of improvement.

Lacrimal gland duct obstruction and dacryops: Unravelling its pathogenesis with proteomics and cellular profiling.

LCA and 3-oxo-LCA mitigate dietary oxysterols-induced loss of barrier function in intestinal epithelial cells.